Cost–Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand

INTRODUCTION: Chronic kidney disease (CKD) creates a significant economic burden on patients and society. The DAPA-CKD trial reports the benefit of dapagliflozin in CKD patients; however, its cost-effectiveness is unknown in Thailand. This study evaluated the cost–utility of dapagliflozin in additio...

Descripción completa

Detalles Bibliográficos
Autores principales: Vareesangthip, Kriengsak, Deerochanawong, Chaicharn, Thongsuk, Dittaya, Pojchaijongdee, Nuch, Permsuwan, Unchalee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918172/
https://www.ncbi.nlm.nih.gov/pubmed/35038121
http://dx.doi.org/10.1007/s12325-021-02037-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918172/
https://www.ncbi.nlm.nih.gov/pubmed/35038121
http://dx.doi.org/10.1007/s12325-021-02037-6

Ejemplares similares